researchdrivelogo.jpg
Global Plasma Therapy Market Predicted to Garner a Revenue of $432.8 Million at a CAGR of 16.3% during the Forecast Period, 2019-2026 - Exclusive report by Research Dive
July 26, 2021 09:03 ET | Research Dive
New York, USA, July 26, 2021 (GLOBE NEWSWIRE) -- According to a recent report by Research Dive, the global plasma therapy market is forecasted to reach $432.8 million by the end of 2026, from $131.9...
InCarda Logo.png
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team
June 09, 2021 08:05 ET | InCarda Therapeutics, Inc.
Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in...
ARC logo.png
Cardiac Rehabilitation Market In North America Is Required To Represent Significant Income Share In The Worldwide: Acumen Research And Consulting
May 26, 2021 10:24 ET | Acumen Research and Consulting
LOS ANGELES, May 26, 2021 (GLOBE NEWSWIRE) -- Cardiac rehabilitation is a customized outpatient program which is designed to help you improve your health and recover from a heart attack, other forms...
AMR Logo.png
U.S. Cardiac Resynchronization Therapy Market to Garner $983.3 Million by 2027: AMR
April 06, 2021 10:15 ET | Allied Market Research
PORTLAND, Ore., April 06, 2021 (GLOBE NEWSWIRE) -- As per the report published by Allied Market Research, the U.S. Cardiac Resynchronization Therapy Market was pegged at $965.6 million in 2019, and...
Healthtech Solutions, Inc. (HLTT), Parent Company of Cutting-Edge Medical Technology Companies, Files Reg A With SEC
March 17, 2021 08:30 ET | Healthtech Solutions, Inc.
March 8, 2021, filing to raise up to $75 million.  Maximum of 1,500,000 shares of Series B preferred stock offered at price of $50 per share.Healthtech Solutions, Inc. is organized to pursue...
Healthtech Solutions, Inc. (HLTT), Parent Company of Medi-Scan Inc., Announces Incorporation of a New Subsidiary Called RevHeart, Inc.
March 16, 2021 08:30 ET | Healthtech Solutions, Inc.
New subsidiary will further the Company’s research into treating COVID-related heart muscle injury.  A patent has been filed for a therapy to ameliorate and potentially repair myocardial damage. NEW...
InCarda Logo.png
InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation
January 19, 2021 08:05 ET | InCarda Therapeutics, Inc.
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
ITGR LOGO (2019-09-25) intgr_ful_r_4cp_hor.png
Integer’s Alden, N.Y. Location Breaks Ground on Building Expansion
January 14, 2021 16:05 ET | Integer Holdings Corporation
~ Expansion to Significantly Increase Plant’s Production Capacity of Xcellion® Lithium Ion Rechargeable Batteries ~ PLANO, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integer Holdings Corporation...
InCarda Logo.png
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
November 13, 2020 10:00 ET | InCarda Therapeutics, Inc.
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of...
InCarda Logo.png
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
October 21, 2020 08:05 ET | InCarda Therapeutics, Inc.
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...